TY - JOUR T1 - NEW CORONAVIRUS IN PREGNANT WOMEN. Maternal and perinatal outcomes JF - medRxiv DO - 10.1101/2021.06.03.21258328 SP - 2021.06.03.21258328 AU - Jaime Sánchez AU - Jorge Espinosa AU - Luis Carlos Caballero AU - B Sara Campana AU - Arelys Quintero AU - Carlos Luo AU - C Jorge Ng AU - Rafael de Gracia AU - Paulino Vigil-De Gracia Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/06/2021.06.03.21258328.abstract N2 - Objectives To report the maternal and neonatal results of patients infected with COVID-19 in Panama.Methods The study is based on the analysis of pregnant women with COVID-19, in 5 hospitals in the Republic of Panama. The inclusion criteria were: Patients with or without symptoms, positive RT-PCR for SARS-CoV-2 in the period from March 23 to 6 months after, whose births were attended in one of those 5 hospitals and who signed the consent. Data was obtained at the time of diagnosis of the infection and at the time of termination of pregnancy for the mother and newborn.Results 253 patients met the inclusion criteria. Most were diagnosed in the third trimester (89.3%). 10.3% of the patients presented in a severe form of COVID-19. The most frequent complication was pre-eclampsia and if we add gestational hypertension they represent 21.2%; most of the patients terminated the pregnancy by caesarean section (58%). 26.9% (95% CI 21.3-32.9%) of the births were premature, and perinatal mortality was 5.4% (95% CI 3.0-9.0%). There was a need for mechanical ventilation in 5.9% (95% CI 3.6-9.6%) of the cohort and there were four maternal deaths (1.6% - 95% CI 0.6-4.0%).Conclusions This study of pregnant women infected with COVID-19 and diagnosed with RT-PCR shows serious maternal complications such as high admission to the ICU, need for mechanical ventilation and one death in every 64 infected. Frequent obstetric complications such as hypertension, premature rupture of membranes, high rate of prematurity and perinatal lethality were also seen.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study was not registeredFunding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the national bioethics committee of Panama, protocol reference: EC-CNBI-2020-04-45.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data is available ER -